China war on healthcare costs lure Indian drugmaker Sun Pharma: Report

Written by Medical Dialogues Bureau Published On 2019-05-06T09:15:31+05:30 | Updated On 16 Aug 2021 11:45 AM IST

China has rolled out an ambitious multi-city bulk procurement program that's driving down prices and providing an opening for Indian manufacturers like Sun Pharma to compete.

New Delhi: Sun Pharmaceutical Industries Ltd. (Sun Pharma) is scouting for a partner in China to help it win a larger piece of the world's second-largest drug market, where the government is on a mission to drive down healthcare costs.

With recovery underway in its US business, Sun Pharma's billionaire founder Dilip Shanghvi is honing in on China and believes market watchers are underestimating the potential there for India's largest drugmaker.

"There is a big opportunity for us," Shanghvi said in an interview with Bloomberg News Editor-in-Chief John Micklethwait in Mumbai on Thursday. "That would create a significant new revenue stream, which is not factored in our valuation when analysts look at it."

China has rolled out an ambitious multi-city bulk procurement program that's driving down prices and providing an opening for Indian manufacturers like Sun Pharma to compete. It's importing more drugs, reimbursing more and speeding up approvals of new medicines to ensure they reach patients faster.

The policy push comes as many generic drugmakers are still reeling from a brutal price war in the world's biggest drug market, the US While Sun Pharma's Indian rivals, like Dr Reddy's Laboratories Ltd. and Cipla Ltd., are already expanding in the Asian nation, Shanghvi has mostly kept mum about his plans there.

India's top drugmaker will start scaling up its China business in six to nine months, according to Shanghvi. The unit will contribute "some percentage" to Sun's $4 billion of overall sales within three years from almost nothing right now, he added.

The $160 billion Chinese drug market "is now a focus for Indian generics" as U.S.-approved drugs are cleared faster, Jefferies analyst Piyush Nahar wrote in a Feb. 27 note.

"While the reforms make China an attractive market, ramp-up and profitability will have significant challenges," Nahar wrote. "Unlike US, distribution is important in China and will need a local partner and higher spend."

Analysts are split on the prospects of Sun Pharma's stock, which has lagged the rise in the S&P BSE Sensex this year. In the last four years, it has plummeted nearly 52 per cent compared to the Sensex's 42 per cent climb.

Sun Pharma's large portfolio of US-approved products should help the drugmaker ramp up its China business with little investment, Shanghvi said.

"We see enormous interest in China for products that we have global rights for," Shanghvi said, adding that the company "would be comfortable making significant financial commitments," in the Asian nation long term.

Also Read: Sun Pharma gets 11 USFDA observations for Dadra plant, BSE asks for response: Report

Asian nationchinaChina businessCiplaDilip ShanghviDr Reddy's LabsDrugmakersgovernmentHealthcarehealthcare costspharmapharma newsSun PharmaUS

Source : Bloomberg

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here